Guggenheim Capital LLC Sells 15,567 Shares of Esperion Therapeutics (ESPR)

Guggenheim Capital LLC trimmed its stake in shares of Esperion Therapeutics (NASDAQ:ESPR) by 28.3% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,528 shares of the biopharmaceutical company’s stock after selling 15,567 shares during the quarter. Guggenheim Capital LLC owned approximately 0.15% of Esperion Therapeutics worth $2,603,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Bank of New York Mellon Corp grew its position in Esperion Therapeutics by 0.7% during the 4th quarter. Bank of New York Mellon Corp now owns 116,224 shares of the biopharmaceutical company’s stock worth $7,652,000 after acquiring an additional 852 shares during the last quarter. First Mercantile Trust Co. grew its position in Esperion Therapeutics by 56.0% during the 4th quarter. First Mercantile Trust Co. now owns 4,233 shares of the biopharmaceutical company’s stock worth $279,000 after acquiring an additional 1,519 shares during the last quarter. Russell Investments Group Ltd. grew its position in Esperion Therapeutics by 8.3% during the 3rd quarter. Russell Investments Group Ltd. now owns 25,072 shares of the biopharmaceutical company’s stock worth $1,257,000 after acquiring an additional 1,913 shares during the last quarter. Rhumbline Advisers grew its position in Esperion Therapeutics by 10.6% during the 3rd quarter. Rhumbline Advisers now owns 20,500 shares of the biopharmaceutical company’s stock worth $1,027,000 after acquiring an additional 1,960 shares during the last quarter. Finally, American International Group Inc. grew its position in Esperion Therapeutics by 21.6% during the 3rd quarter. American International Group Inc. now owns 11,257 shares of the biopharmaceutical company’s stock worth $564,000 after acquiring an additional 2,001 shares during the last quarter. Institutional investors and hedge funds own 91.66% of the company’s stock.

How to Become a New Pot Stock Millionaire

Several equities analysts recently issued reports on ESPR shares. BidaskClub lowered Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, March 20th. Chardan Capital raised their price target on Esperion Therapeutics from $75.00 to $100.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 27th. Stifel Nicolaus set a $105.00 price target on Esperion Therapeutics and gave the stock a “buy” rating in a research report on Monday, January 15th. Credit Suisse Group began coverage on Esperion Therapeutics in a research report on Wednesday, January 17th. They set an “outperform” rating and a $103.00 price target on the stock. Finally, JMP Securities lifted their price objective on Esperion Therapeutics from $60.00 to $153.00 and gave the stock an “outperform” rating in a research report on Thursday, March 8th. Six equities research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Esperion Therapeutics presently has an average rating of “Buy” and a consensus target price of $92.54.

Shares of ESPR stock opened at $73.31 on Thursday. The company has a market capitalization of $1,783.14, a PE ratio of -10.50 and a beta of 2.51. Esperion Therapeutics has a fifty-two week low of $30.95 and a fifty-two week high of $82.68.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.80) by $0.36. During the same period in the prior year, the business earned ($1.29) earnings per share. equities research analysts anticipate that Esperion Therapeutics will post -5.61 earnings per share for the current year.

In other news, Director Nicole Vitullo sold 11,674 shares of the firm’s stock in a transaction that occurred on Thursday, January 25th. The stock was sold at an average price of $71.79, for a total value of $838,076.46. Following the completion of the transaction, the director now owns 3,177 shares in the company, valued at approximately $228,076.83. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Roger S. Newton sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 29th. The shares were sold at an average price of $72.37, for a total value of $1,809,250.00. Following the completion of the transaction, the director now owns 639,682 shares of the company’s stock, valued at approximately $46,293,786.34. The disclosure for this sale can be found here. 32.50% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/04/12/guggenheim-capital-llc-sells-15567-shares-of-esperion-therapeutics-espr.html.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply